Inhibition of folate metabolism in chemotherapy: the origins and uses of co-trimoxazole
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
1983
|
| Schriftenreihe: | Handbook of experimental pharmacology
64 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXI, 457 S. Ill., graph. Darst. |
| ISBN: | 3540117822 0387117822 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV000077338 | ||
| 003 | DE-604 | ||
| 005 | 20150923 | ||
| 007 | t | ||
| 008 | 870612s1983 ad|| |||| 00||| eng d | ||
| 020 | |a 3540117822 |9 3-540-11782-2 | ||
| 020 | |a 0387117822 |9 0-387-11782-2 | ||
| 035 | |a (OCoLC)8667843 | ||
| 035 | |a (DE-599)BVBBV000077338 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-19 |a DE-355 |a DE-210 |a DE-20 |a DE-11 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a RM666.C567 | |
| 082 | 0 | |a 615/.7 |2 19 | |
| 082 | 0 | |a 615/.1 |2 19 | |
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a QV 4 |2 nlm | ||
| 245 | 1 | 0 | |a Inhibition of folate metabolism in chemotherapy |b the origins and uses of co-trimoxazole |c contributors J. F. Acar ... Ed. G. H. Hitchings |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1983 | |
| 300 | |a XXI, 457 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 64 | |
| 650 | 7 | |a Folic Acid |2 cabt | |
| 650 | 7 | |a Antimetabolites |2 cabt | |
| 650 | 7 | |a Sulfamethoxazole |2 cabt | |
| 650 | 7 | |a Pharmacodynamics |2 cabt | |
| 650 | 7 | |a Trimethoprim |2 cabt | |
| 650 | 7 | |a Antibiotica |2 gtt | |
| 650 | 4 | |a Antifoliques | |
| 650 | 4 | |a Cotrimoxazole - Effets physiologiques | |
| 650 | 7 | |a Farmacodynamica |2 gtt | |
| 650 | 7 | |a Foliumzuur |2 gtt | |
| 650 | 7 | |a Inhibitie |2 gtt | |
| 650 | 7 | |a Stofwisseling |2 gtt | |
| 650 | 7 | |a Sulfonamiden |2 gtt | |
| 650 | 7 | |a Trimethoprim |2 gtt | |
| 650 | 4 | |a Co-trimoxazole |x Physiological effect | |
| 650 | 4 | |a Folic Acid |x metabolism | |
| 650 | 4 | |a Folic acid |x Antagonists | |
| 650 | 4 | |a Sulfamethoxazole |x pharmacology | |
| 650 | 4 | |a Trimethoprim |x pharmacology | |
| 650 | 0 | 7 | |a Cotrimoxazol |0 (DE-588)4148337-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Folsäure |0 (DE-588)4121288-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Folate |0 (DE-588)4154952-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Cotrimoxazol |0 (DE-588)4148337-6 |D s |
| 689 | 0 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Folsäure |0 (DE-588)4121288-5 |D s |
| 689 | 1 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Folate |0 (DE-588)4154952-1 |D s |
| 689 | 2 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 2 | |5 DE-604 | |
| 700 | 1 | |a Hitchings, George H. |d 1905-1998 |e Sonstige |0 (DE-588)110178602 |4 oth | |
| 700 | 1 | |a Acar, Jacques F. |d 1931-2020 |e Sonstige |0 (DE-588)171944666 |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 64 |w (DE-604)BV002390716 |9 64 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-000035270 | ||
Datensatz im Suchindex
| _version_ | 1804114532434444288 |
|---|---|
| adam_text | 1 -- 26 0 2 - -&% INHIBITION OF FOLATE METABOLISM IN CHEMOTHERAPY THE
ORIGINS AND USES OF CO-TRIMOXAZOLE CONTRIBUTORS J. F. ACAR * N. ANAND *
D. W BARRY * R. E. BLACK * J. J. BURCHALL S. R. M. BUSHBY * M. L.
CLEMENTS * A. D. DAYAN R. E. DESJARDINS * F. W. GOLDSTEIN * L.T. GUTMAN
* I. HANSEN G. H. HITCHINGS * D. T. D. HUGHES * G. T. KEUSCH * D. H.
LAWSON M. M. LEVINE * F O GRADY * K. H. PATTISHALL * I. M. ROLLO B. ROTH
* J. K. SEYDEL * C. W SIGEL * T. A. STAMEY * W E. STAMM C. M. WILFERT *
G. P. WORMSER EDITOR G. H. HITCHINGS UNIVERSITATS- BIBLIOTHEK
SPRINGER-VERLAG BERLIN HEIDELBERG NEW YORK 1983 CONTENTS
TRIMETHOPRIM/SULFAMETHOXAZOLE: AN OVERVIEW. G. P. WORMSER AND G. T.
KEUSCH. WITH 1 FIGURE A. INTRODUCTION 1 B. MECHANISMS OF ACTION 1 C.
RESISTANCE 3 I. CHROMOSOME-MEDIATED RESISTANCE 3 II. PLASMID-MEDIATED
RESISTANCE 4 III. THYMIDINE DEPENDENCE 4 D. CLINICAL USE OF TMP/SMX 5 I.
APPROVED INDICATIONS IN THE UNITED STATES 5 II. OTHER IMPORTANT USES 5
E. USE OF TMP OR SMX AS SINGLE AGENTS 6 F. ADVERSE EFFECTS 6 G. SUMMARY
7 REFERENCES 7 PHARMACOLOGY AND BIOCHEMISTRY CHAPTER 1 - FUNCTIONS OF
TETRAHY DROFOLATE AND THE ROLE OF DIHYDROFOLATE REDUCTASE IN CELLULAR
METABOLISM. G. H. HITCHINGS. WITH 6 FIGURES A. GENERAL 11 B. OCCURRENCE
OF FOLATES 11 C. FUNCTIONS OF TETRAHYDROFOLATE: COFACTORS 12 I. FORMATE
AND EQUIVALENTS 12 1. PURINE BIOSYNTHESIS 13 II. FORMALDEHYDE
EQUIVALENTS, HYDROXYMETHYL, AND METHYL DERIVATIVES 14 1. METHIONINE
BIOSYNTHESIS 14 2. THYMIDYLATE SYNTHESIS 15 3. VITAMINS AND OTHER
METABOLITES 16 D. ORIGINS OF CELLULAR FOLATES 16 E. TRANSPORT SYSTEMS 17
I. SELECTIVE RESCUE . 18 F. MECHANISM OF ACTION OF TMP/SMX 18 I.
THYMINELESS DEATH 20 X CONTENTS G. SUMMARY 20 REFERENCES 20 CHAPTER 2
SULFONAMIDES: STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISM OF ACTION.
N. ANAND. WITH 1 FIGURE A. INTRODUCTION 25 B. DEVELOPMENT OF
SULFONAMIDES AND SULFONES 26 I. SULFONAMIDES 26 II. SULFONES 29 III.
ANTIMICROBIAL SPECTRUM 30 C. STRUCTURE AND BIOLOGICAL ACTIVITY 31 I.
STRUCTURE-ACTIVITY RELATIONSHIP 31 II. PHYSICOCHEMICAL PROPERTIES AND
ANTIMICROBIAL ACTIVITY 32 1. WATER SOLUBILITY 34 2. LIPID SOLUBILITY 36
3. PROTEIN BINDING 36 III. PHARMACOKINETICS AND METABOLISM 37 1.
SULFONAMIDES 37 2. SULFONES 38 IV. HALF-LIFE 38 D. MODE OF ANTIMICROBIAL
ACTION 39 I. FOLIC ACID METABOLISM 39 II. ACTION OF SULFONAMIDES AND
SULFONES 41 1. SELECTIVITY OF ACTION 44 III. SYNERGISM WITH
DIHYDROFOLATE REDUCTASE INHIBITORS 45 IV. DRUG RESISTANCE 45 E. PRESENT
STATUS IN THERAPEUTICS 46 REFERENCES 47 CHAPTER 3 DIHYDROFOLATE
REDUCTASE. J. J. BURCHALL A. INTRODUCTION 55 B. ASSAY AND KINETIC
STUDIES 56 C. MECHANISM OF ACTION 57 D. BASIS OF SELECTIVITY 58 I.
KINETIC STUDIES 58 II. INHIBITOR BINDING ANALYSIS 59 III. ENZYME
CONFORMATION AND COOPERATIVITY 62 IV. AMINO ACID SEQUENCES 63 V.
THREE-DIMENSIONAL STRUCTURES OF DHFR 65 E. PLASMID-CODED REDUCTASES 68
F. GENETICS OF DHFR 69 REFERENCES 70 CONTENTS XI CHAPTER 4 ANTIBACTERIAL
ACTIVITY. S. R. M. BUSHBY. WITH 4 FIGURES A. INTRODUCTION 75 B. IN VITRO
ACTIVITY 75 I. EFFECTS OF MEDIUM AND SIZE OF INOCULUM 75 II.
BACTERIOSTATIC ACTIVITY 77 III. BACTERICIDAL ACTIVITY 80 IV.
DEMONSTRATION OF SYNERGY 80 C. SYNERGY AND SULFONAMIDE-RESISTANT STRAINS
86 D. REVERSAL OF ACTIVITY OF TMP 87 E. DEVELOPMENT OF RESISTANCE 87 F.
SPECTRUM OF ACTIVITY OF TMP/SMX 90 G. CHOICE OF SULFONAMIDE 92 H.
2,4-DIAMINOPYRIMIDINES AS SINGLE AGENTS 94 J. SUSCEPTIBILITY TESTING 96
REFERENCES 99 CHAPTER 5 SELECTIVE INHIBITORS OF BACTERIAL DIHYDROFOLATE
REDUCTASE: STRUCTURE-ACTIVITY RELATIONSHIPS. B. ROTH. WITH 2 FIGURES A.
INTRODUCTION 107 B. HISTORICAL PERSPECTIVE 109 C. SOME GENERAL
REQUIREMENTS FOR DHFR INHIBITION AND ANTIBACTERIAL ACTIVITY ILL D.
INHIBITORS OF SPECIFIC DHFRS ILL I. THE 5-PHENYL DERIVATIVES AND RELATED
COMPOUNDS ILL II. 5-BENZYL-2,4-DIAMINOPYRIMIDINES AND CLOSE RELATIVES
112 1. THE 6-UNSUBSTITUTED DERIVATIVES .112 2. 6-SUBSTITUTED DERIVATIVES
115 3. SUBSTITUTION OF A HETEROCYCLIC RING FOR THE BENZENE MOIETY . .
116 4. VARIATIONS IN THE BRIDGE BETWEEN THE PYRIMIDINE AND BENZENE RINGS
116 III. THE 1,2-DIHYDRO-1,3,5-TRIAZINES 117 IV. BICYCLIC ANALOGS OF THE
DIAMINOPYRIMIDINES 117 E. DISCUSSION 118 F. CONCLUSION 121 REFERENCES
122 CHAPTER 6 KINETICS OF ANTIBACTERIAL EFFECTS. J. K. SEYDEL. WITH 19
FIGURES A. INTRODUCTION: BACTERIAL GROWTH KINETICS IN THE PRESENCE OF
FOLATE INHIBITORS 129 B. SULFONAMIDES (SYNTHETASE INHIBITORS) 131 I.
EFFECT OF SULFONAMIDES ON GENERATION RATES OF E. COLI 131 XII CONTENTS
C. TRIMETHOPRIM (TMP): DIHYDROFOLATE REDUCTASE INHIBITOR 133 I. EFFECT
OF TMP ON GENERATION RATES OF E. COLI 133 II. INFLUENCE OF TMP
CONCENTRATION AND INOCULUM SIZE ON THE BACTERICIDAL EFFECT OF TMP 135
III. REVERSIBILITY OF TMP ACTION 137 IV. INFLUENCE OF CULTURE BROTH
CONSTITUENTS ON BIPHASIC INHIBITION . .138 V. DEVELOPMENT OF RESISTANCE
AGAINST DIHYDROFOLIC ACID REDUCTASE INHIBITORS 142 D. COMBINED ACTION OF
SULFONAMIDES AND TRIMETHOPRIM (FOLATE INHIBITORS) 143 I. EFFECT OF
TMP/SMX ON GENERATION RATES OF E. COLI 143 II. INFLUENCE OF INHIBITORY
POWER AND CONCENTRATION OF SULFONAMIDES OR SULFONES ON THE DEGREE OF
SYNERGISM 145 III. INFLUENCE OF INHIBITORY POWER OF TMP DERIVATIVES ON
THE DEGREE OF SYNERGISM AND MAXIMAL POSSIBLE EFFECT 151 IV. SELECTION
CRITERIA FOR COMBINATION OF TMP AND TMP DERIVATIVES WITH SULFONAMIDES
151 V. MODE OF ACTION OF SULFONAMIDES, TMP, AND THEIR COMBINATIONS 155
1. SULFONAMIDES 155 2. TMP 156 3. COMBINATIONS OF SULFONAMIDES AND TMP
158 REFERENCES 158 CHAPTER 7 DISPOSITION AND METABOLISM OF TRIMETHOPRIM,
TETROXOPRIM, SULFAMETHOXAZOLE, AND SULFADIAZINE. C. W. SIGEL. WITH 4
FIGURES A. INTRODUCTION 163 B. DRUG DISPOSITION 163 I. DRUG ABSORPTION
163 II. DISTRIBUTION INTO BIOLOGIC FLUIDS AND TISSUES . . . . . . . . .
. 164 1. PHYSICOCHEMICAL PROPERTIES THAT INFLUENCE DISTRIBUTIONS . . .
.164 2. RELATIONSHIP BETWEEN PLASMA AND TISSUE CONCENTRATIONS . . .164
III. EXCRETION 168 IV. METABOLISM 169 1. TRIMETHOPRIM 169 2. TETROXOPRIM
173 3. SULFAMETHOXAZOLE 174 4. SULFADIAZINE 175 C. DRUG ASSAY METHODS
177 I. TRIMETHOPRIM AND RELATED BENZYLPYRIMIDINES 177 1.
SPECTROFLUOROMETRIC METHODS 177 2. QUANTITATIVE THIN LAYER
CHROMATOGRAPHY 177 3. HIGH PRESSURE LIQUID CHROMATOGRAPHIC METHODS 178
4. GAS-LIQUID CHROMATOGRAPHIC ANALYSIS 178 5. MICROBIOLOGIC PROCEDURES
178 6. OTHER METHODS 179 CONTENTS XIII II. SULFONAMIDES 1.
SPECTROPHOTOMETRIC METHODS 179 2. QUANTITATIVE THIN LAYER CHROMATOGRAPHY
179 3. HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS 180 D. CONCLUSION 180
REFERENCES 180 CHAPTER 8 PRECLINICAL TOXICITY TESTING OF CO-TRIMOXAZOLE
AND OTHER TRIMETHOPRIM/ SULFONAMIDE COMBINATIONS. A. D. DAYAN A.
INTRODUCTION 185 B. GENERAL PHARMACODYNAMIC ACTIONS 185 I. TRIMETHOPRIM
185 II. TRIMETHOPRIM AND SULFAMOXOLE 186 C. ACUTE TOXICITY 186 I.
TRIMETHOPRIM, SULFAMETHOXAZOLE, AND CO-TRIMOXAZOLE 186 II. TRIMETHOPRIM
AND SULFAMETHOXYPYRIDAZINE 187 D. SUBACUTE AND CHRONIC TOXICITY TESTS
188 I. TRIMETHOPRIM 188 1. RATS 188 2. MONKEYS 189 3. OTHER SPECIES 190
II. TRIMETHOPRIM AND SULFAMETHOXAZOLE 190 1. RATS 190 .2. RABBITS 192 3.
MONKEYS 192 E. COMBINATIONS OF TRIMETHOPRIM AND OTHER SULFONAMIDES 192
I. TRIMETHOPRIM AND SULFAFURAZOLE . . 192 II. TRIMETHOPRIM AND
SULFADIAZINE .192 III. TRIMETHOPRIM AND SULFAMOXOLE 193 IV. TRIMETHOPRIM
AND SULFAMETHOXYPYRAZINE 194 F. SPECIAL STUDIES OF THE THYROID AND
TRIMETHOPRIM/SULFONAMIDE COMBINATIONS 194 G. OTHER ACTIONS OF
TRIMETHOPRIM ALONE OR COMBINED WITH SULFONAMIDES 195 I. CO-TRIMOXAZOLE
AND IMMUNOSUPPRESSION 195 II. LOCAL EFFECTS OF INTRAMUSCULAR INJECTION
OF TRIMETHOPRIM AND VARIOUS SULFONAMIDES 195 III. CO-TRIMOXAZOLE AND
RENAL FAILURE 196 H. REPRODUCTIVE TOXICOLOGY 196 I. FETAL TOXICITY TESTS
196 1. RATS 196 2. RABBITS 198 II. FERTILITY TESTS 198 1. RATS 198 2.
RABBITS 199 XIV CONTENTS 3. HAMSTERS 199 4. CONCLUSIONS 199 5. OTHER
RELATED INFORMATION 200 III. REPRODUCTIVE TOXICITY OF TRIMETHOPRIM
COMBINED WITH OTHER SULFONAMIDES 200 1. TRIMETHOPRIM AND SULFAMOXOLE 200
2. TRIMETHOPRIM AND SULFAMETHOXYPYRAZINE 201 J. MUTAGENICITY 201 I.
POINT MUTATION TESTS IN BACTERIA 201 II. HUMAN CYTOGENETIC STUDIES 201
REFERENCES 202 CLINICAL PHARMACOLOGY CHAPTER 9 ADVERSE EFFECT OF
CO-TRIMOXAZOLE. D. H. LAWSON. WITH 5 FIGURES A. INTRODUCTION 207 B.
GASTROINTESTINAL DISORDERS 209 I. UPPER GASTROINTESTINAL SYMPTOMS 209
II. LOWER GASTROINTESTINAL SYMPTOMS 210 C. SKIN DISORDERS 210 I. TOXIC
ERYTHEMA 214 II. OTHER SKIN REACTIONS 215 III. SULFAMETHOXAZOLE OR
TRIMETHOPRIM? 216 D. RENAL DISORDERS 216 E. HAEMATOLOGICAL DISORDERS 218
I. FOLIC ACID DEFICIENCY *. . . . 218 II. LEUCOPENIA/AGRANULOCYTOSIS
218 III. THROMBOCYTOPENIA 220 IV. HAEMOLYTIC ANAEMIA 220 F. JAUNDICE 221
I. LIVER DAMAGE 221 II. HYPERBILIRUBINAEMIA OF THE NEWBORN 221 G.
PREGNANCY 221 H. MISCELLANEOUS 222 J. DRUG INTERACTIONS 222 I.
PYRIMETHAMINE 222 II. AZATHIOPRINE 223 III. WARFARIN 223 IV. PHENYTOIN
223 V. HYPOGLYCAEMIC AGENTS 224 K. CONCLUSIONS 224 REFERENCES 224
CONTENTS XV CHAPTER 10 CLINICAL PHARMACOKINETICS OF CO-TRIMOXAZOLE. I.
HANSEN A. INTRODUCTION 229 B. ABSORPTION AND BIOLOGIC HALF-LIVES 229 C.
DISTRIBUTION 231 I. PLASMA 231 II. CEREBROSPINAL FLUID 232 III. AQUEOUS
HUMOR 232 IV. BREAST MILK 232 V. PROSTATIC AND SEMINAL MATERIAL 233 VI.
VAGINAL FLUID 233 VII. PLACENTAL AND FETAL MATERIAL 233 VIII. BILE FLUID
233 IX. ERYTHROCYTES 234 X. BONE 234 XI. OTHER TISSUES AND ORGANS 234 D.
METABOLISM 234 E. ELIMINATION 235 F. INTERACTIONS 238 REFERENCES 238
CHAPTER 11 RESISTANCE: GENETICS AND MEDICAL IMPLICATIONS: J. F. ACAR AND
F. W. GOLDSTEIN A. INTRODUCTION 243 B. RESISTANCE TO SULFONAMIDES 243 I.
DEFINITION 243 II. NATURAL RESISTANCE 243 III. ACQUIRED RESISTANCE 243
C. RESISTANCE TO TRIMETHOPRIM . 243 I. DEFINITION 243 II. NATURAL
RESISTANCE 244 III. ACQUIRED RESISTANCE 244 D. MECHANISMS OF ACQUIRED
RESISTANCE TO SULFONAMIDES 244 I. RESULTS OF MUTATIONS 244 1. DECREASED
PERMEABILITY 244 2. HYPERPRODUCTION OF P-AMINOBENZOIC ACID 244 3.
ALTERED DIHYDROPTEROATE SYNTHASE 245 II. ACQUISITION OF R FACTORS 245 E.
MECHANISM OF ACQUIRED RESISTANCE TO TRIMETHOPRIM 245 I. BY MUTATION 245
1. THYMINELESS ORGANISMS 245 2. MODIFICATION OF DIHYDROFOLATE REDUCTASE
246 II. PLASMID-MEDIATED RESISTANCE 247 1. TRANSFERABLE 248 2.
NONTRANSFERABLE 248 XVI CONTENTS F. MEDICAL IMPLICATIONS 248 I.
SULFONAMIDE-RESISTANT STRAINS 248 II. SULFONAMIDE-SENSITIVE,
TRIMETHOPRIM-RESISTANT STRAINS 249 III. EMERGENCE OF RESISTANT STRAINS
DURING THERAPY 249 G. EPIDEMIOLOGIC OVERVIEW OF RESISTANCE TO
TRIMETHOPRIM 250 I. GRAM-POSITIVE BACTERIA 250 II. GRAM-NEGATIVE
BACTERIA 250 REFERENCES 252 CLINICAL STUDIES CHAPTER 12 TRIMETHOPRIM
ALONE: CLINICAL USES. D. W. BARRY AND K. H. PATTISHALL. WITH 2 FIGURES
A. INTRODUCTION 261 B. MICROBIOLOGIC AND PHARMACOKINETIC PROPERTIES 261
C. RELATION OF SENSITIVITIES AND PHARMACOKINETICS TO THERAPY OF URINARY
TRACT INFECTIONS 264 I. GENERAL 264 II. UNCOMPLICATED URINARY TRACT
INFECTIONS 267 III. COMPLICATED URINARY TRACT INFECTIONS 271 D.
PROPHYLAXIS 273 I. RECURRING URINARY INFECTION IN WOMEN AND CHILDREN 273
II. IMMUNOSUPPRESSED PATIENTS 275 E. ADVERSE REACTIONS AND SAFETY 276 I.
GENERAL 276 II. DERMATOLOGIC 277 III. GASTROINTESTINAL , 280 IV.
HEMATOLOGIC 280 F. BACTERIAL RESISTANCE 281 I. GENERAL 281 II. FINNISH
EXPERIENCE 282 III. EFFECT ON FECAL FLORA 286 G. CONCLUSION 286
REFERENCES 287 CHAPTER 13 INHIBITORS OF DIHYDROFOLATE REDUCTASE AS
ANTIPROTOZOAL AGENTS. I. M. ROLLO. WITH 4 FIGURES A. INTRODUCTION 293 B.
POINTS OF POSSIBLE THERAPEUTIC ATTACK 295 CONTENTS XVII C. ANTIMALARIAL
THERAPEUTICS 296 I. EARLY TRIALS 297 II. CLINICAL CURE WITH
PYRIMETHAMINE 298 III. CAUSAL PROPHYLAXIS 299 IV. SUPPRESSION AND MASS
PROPHYLAXIS 300 V. GAMETOCYTICIDAL EFFECTS 301 VI. RADICAL CURE 302 VII.
DRUG RESISTANCE 303 VIII. COMBINATION WITH SULFONAMIDES AND SULFONES 303
1. SUPPRESSIVE AND CLINICAL CURE 303 2. EFFECT ON OTHER SPOROZOA 305
REFERENCES 306 CHAPTER 14 PEDIATRIC USES OF SULFONAMIDES, TRIMETHOPRIM,
AND THE COMBINATION. L. T. GUTMAN AND C. M. WILFERT A. INTRODUCTION 309
B. HEMOPHILUS INFLUENZAE INFECTIONS 309 I. OTITIS MEDIA 310 1. ACUTE 310
2. SEROUS AND CHRONIC 311 II. SINUSITIS 311 III. PROPHYLAXIS TO PREVENT
SECONDARY INFECTION 312 C. MENINGITIS 314 D. URINARY TRACT INFECTIONS
315 I. ACUTE 315 II. STRUCTURAL DEFECTS OF THE URINARY SYSTEM . 315 III.
PREVENTION .315 IV. THERAPY OF PERIURETHRAL AND RECTAL FLORA .316 V.
CHLAMYDIAL INFECTIONS 316 E. PNEUMOCYSTIS CARINII PNEUMONIA 318 I.
THERAPY 318 II. PREVENTION 319 F. ENTERIC DISEASES 320 I. SALMONELLOSIS
320 II. SHIGELLOSIS 321 III. YERSINIA INFECTIONS 322 1. ACUTE ENTERITIS
323 2. CHRONIC ENTERITIS 323 3. MESENTERIC ADENITIS 323 G. MISCELLANEOUS
CONDITIONS 324 I. CHRONIC GRANULOMATOUS DISEASE 324 II. OSTEOMYELITIS
324 III. ASCENDING CHOLANGITIS 324 REFERENCES 325 XVIII CONTENTS CHAPTER
15 USE OF CO-TRIMOXAZOLE IN URINARY TRACT INFECTION. F. O GRADY. WITH 2
FIGURES A. INTRODUCTION 331 B. CO-TRIMOXAZOLE IN ACUTE URINARY TRACT
INFECTION 331 I. EPIDEMIOLOGY OF RESISTANCE 332 1. TYPES OF RESISTANCE
332 II. EFFECTS OF CARRIAGE SITES 333 1. EFFECT ON GUT FLORA 333 2.
EFFECT ON URETHRAL COLONISATION 334 III. OVERTREATMENT 334 C. CONTROL OF
RECURRENT INFECTION 335 D. ROLE OF THE COMBINATION 337 I. CONTRASTING
EFFECTS OF TRIMETHOPRIM AND SULFONAMIDE IN THE URINE 337 II. TOXICITY
339 REFERENCES 339 CHAPTER 16 TREATMENT OF GENITAL INFECTIONS WITH
TRIMETHOPRIM, SULFONAMIDES, AND COMBINATIONS. W. E. STAMM A.
INTRODUCTION 343 B. TREATMENT OF GONORRHEA WITH
TRIMETHOPRIM/SULFAMETHOXAZOLE . . . . 343 I. UNCOMPLICATED ANOGENITAL
INFECTION 343 II. RECTAL INFECTION 348 III. PHARYNGEAL INFECTION 348 IV.
IN VITRO STUDIES AND TREATMENT OF GONORRHEA WITH TRIMETHOPRIM/
SULFAMETHOXAZOLE 348 C. INFECTIONS DUE TO CHLAMYDIA TRACHOMATIS 350 I.
POSTGONOCOCCAL URETHRITIS 350 II. NONGONOCOCCAL URETHRITIS 351 III.
LYMPHOGRANULOMA VENEREUM 352 D. CHANCROID 352 E. SYPHILIS 354 REFERENCES
354 CHAPTER 17 TREATMENT OF ENTERIC INFECTIONS AND COMBINATIONS. M. L.
CLEMENTS, R. E. BLACK, AND M. M. LEVINE A. ESCHERICHIA COLI DIARRHEA 357
I. INTRODUCTION 357 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF E.
COLI DIARRHEA . .357 1. IN VITRO STUDIES 357 2. CLINICAL STUDIES 358
III. SUMMARY 358 CONTENTS XIX B. ISOSPORA BELLI INFECTIONS 358 I.
INTRODUCTION 358 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF AN
ISOSPORA BELLI INFECTION 359 C. SALMONELLA INFECTIONS 359 I.
INTRODUCTION 359 1. TYPHOIDAL AND PARATYPHOIDAL SALMONELLA INFECTIONS
359 2. NON-TYPHOIDAL SALMONELLA INFECTIONS 360 II.
TRIMETHOPRIM/SULFAMETHOXAZOLE IN THE TREATMENT OF SALMONELLA TYPHI
INFECTIONS 361 1. THERAPEUTIC STUDIES IN ANTIBIOTIC-SENSITIVE S. TYPHI
INFECTIONS . 361 2. STUDIES IN INFECTIONS DUE TO
CHLORAMPHENICOL-RESISTANT S. TYPHI STRAINS 363 3.
TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF TYPHOID CARRIERS 364 4.
ADVERSE EFFECTS 365 5. SUMMARY 365 III. TRIMETHOPRIM ALONE IN TREATMENT
OF ENTERIC FEVER 366 IV. TRIMETHOPRIM/SULFAMETHOXAZOLE THERAPY IN
NON-TYPHOIDAL SALMONELLOSIS 366 1. IN VITRO STUDIES 366 2. CLINICAL
STUDIES 367 3. SUMMARY 368 D. SHIGELLA 368 I. INTRODUCTION 368 II.
TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT IN SHIGELLOSIS . . . . 369 1. IN
VITRO STUDIES 369 2. CLINICAL STUDIES 370 3. SUMMARY 371 E. VIBRIO
CHOLERAE INFECTIONS 371 I. INTRODUCTION : . 371 II.
TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT IN CHOLERA . . . . * . 372 1. IN
VITRO STUDIES .372 2. CLINICAL STUDIES 372 3. SUMMARY 373 F. YERSINIA
ENTEROCOLITICA INFECTIONS 373 I. INTRODUCTION 373 II.
TRIMETHOPRIM/SULFAMETHOXAZOLE AND YERSINIA ENTEROCOLITICA . . . 374 1.
IN VITRO STUDIES 374 2. CLINICAL REPORT 375 3. SUMMARY 375 REFERENCES
375 CHAPTER 18 PROSTATITIS. T. A. STAMEY. WITH 1 FIGURE A. INTRODUCTION
379 B. CLASSIFICATION AND DESCRIPTION OF PATIENT CATEGORIES 379 XX
CONTENTS C. ACUTE AND CHRONIC BACTERIAL PROSTATITIS 382 I. DIAGNOSIS 382
II. PATHOLOGY 384 III. PROSTATIC IMMUNOGLOBULINS 384 IV. THE
ANTIBACTERIAL FACTOR IN PROSTATIC FLUID 385 V. TREATMENT 386 D.
NONBACTERIAL PROSTATITIS 390 REFERENCES 392 CHAPTER 19 CO-TRIMOXAZOLE IN
CHEST INFECTIONS INCLUDING ITS LONG-TERM USE IN CHEST DISEASE. D. T. D.
HUGHES A. INTRODUCTION 397 B. EXACERBATIONS OF CHRONIC BRONCHITIS 397 I.
LEVELS OF TWO COMPONENTS IN SPUTUM 399 II. COMPARATIVE TRIALS 400 C.
OTHER ACUTE CONDITIONS 402 I. PNEUMOCYSTIS CARINII PNEUMONIA 403 D.
LONG-TERM TREATMENT 404 E. PARENTERAL TMP/SMX 406 F. ALTERNATIVE DRUGS
406 G. TRIMETHOPRIM ALONE 407 H. FUTURE DEVELOPMENTS 408 REFERENCES 409
CHAPTER 20 TREATMENT OF MISCELLANEOUS AND UNUSUAL INFECTIONS WITH
TRIMETHOPRIM AND TRIMETHOPRIM/SULFONAMIDE COMBINATIONS. R. E. DESJARDINS
A. INTRODUCTION 411 B. BRUCELLOSIS 411 C. TOXOPLASMOSIS 414 D.
NOCARDIOSIS 417 E. ATYPICAL MYCOBACTERIA 421 F. MYCOSES 422 I.
HISTOPLASMOSIS 422 II. PARACOCCIDIOIDOMYCOSIS 423 III. PHYCOMYCOSIS 424
IV. CHROMOMYCOSIS 425 G. PSEUDOMONAS INFECTIONS 425 I. PSEUDOMONAS
PSEUDOMALLEI 426 II. PSEUDOMONAS CEPACIA AND PSEUDOMONAS MALTOPHILIA 427
H. OTHER INFECTIONS 428 I. BUBONIC PLAGUE 429 CONTENTS XXI II.
RICKETTSIOSIS 429 1. BOUTONNEUSE FEVER 430 2. Q FEVER 430 III.
LEGIONELLA PNEUMOPHILA AND PITTSBURGH PNEUMONIA AGENT INFECTIONS 430 IV.
ISOSPORA BELLI INFECTIONS 430 V. MALAKOPLAKIA 431 VI. PEDICULOSIS 431
REFERENCES 431 SUBJECT INDEX 441
|
| any_adam_object | 1 |
| author_GND | (DE-588)110178602 (DE-588)171944666 |
| building | Verbundindex |
| bvnumber | BV000077338 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 RM666.C567 |
| callnumber-search | QP905 RM666.C567 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | XI 1701 |
| ctrlnum | (OCoLC)8667843 (DE-599)BVBBV000077338 |
| dewey-full | 615/.7 615/.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.7 615/.1 |
| dewey-search | 615/.7 615/.1 |
| dewey-sort | 3615 17 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02905nam a2200769 cb4500</leader><controlfield tag="001">BV000077338</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150923 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1983 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540117822</subfield><subfield code="9">3-540-11782-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387117822</subfield><subfield code="9">0-387-11782-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)8667843</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000077338</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-210</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM666.C567</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.7</subfield><subfield code="2">19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhibition of folate metabolism in chemotherapy</subfield><subfield code="b">the origins and uses of co-trimoxazole</subfield><subfield code="c">contributors J. F. Acar ... Ed. G. H. Hitchings</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1983</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 457 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">64</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Folic Acid</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antimetabolites</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sulfamethoxazole</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacodynamics</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trimethoprim</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibiotica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antifoliques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cotrimoxazole - Effets physiologiques</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacodynamica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Foliumzuur</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inhibitie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stofwisseling</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sulfonamiden</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trimethoprim</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Co-trimoxazole</subfield><subfield code="x">Physiological effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic Acid</subfield><subfield code="x">metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic acid</subfield><subfield code="x">Antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sulfamethoxazole</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trimethoprim</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cotrimoxazol</subfield><subfield code="0">(DE-588)4148337-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Folsäure</subfield><subfield code="0">(DE-588)4121288-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Folate</subfield><subfield code="0">(DE-588)4154952-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cotrimoxazol</subfield><subfield code="0">(DE-588)4148337-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Folsäure</subfield><subfield code="0">(DE-588)4121288-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Folate</subfield><subfield code="0">(DE-588)4154952-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hitchings, George H.</subfield><subfield code="d">1905-1998</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)110178602</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Acar, Jacques F.</subfield><subfield code="d">1931-2020</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)171944666</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">64</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">64</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000035270</subfield></datafield></record></collection> |
| id | DE-604.BV000077338 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T15:08:13Z |
| institution | BVB |
| isbn | 3540117822 0387117822 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-000035270 |
| oclc_num | 8667843 |
| open_access_boolean | |
| owner | DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-210 DE-20 DE-11 DE-188 DE-578 |
| owner_facet | DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-210 DE-20 DE-11 DE-188 DE-578 |
| physical | XXI, 457 S. Ill., graph. Darst. |
| publishDate | 1983 |
| publishDateSearch | 1983 |
| publishDateSort | 1983 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings Berlin [u.a.] Springer 1983 XXI, 457 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 64 Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd rswk-swf Folsäure (DE-588)4121288-5 gnd rswk-swf Folate (DE-588)4154952-1 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Cotrimoxazol (DE-588)4148337-6 s Chemotherapie (DE-588)4127083-6 s DE-604 Folsäure (DE-588)4121288-5 s Folate (DE-588)4154952-1 s Hitchings, George H. 1905-1998 Sonstige (DE-588)110178602 oth Acar, Jacques F. 1931-2020 Sonstige (DE-588)171944666 oth Handbook of experimental pharmacology 64 (DE-604)BV002390716 64 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole Handbook of experimental pharmacology Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd Folsäure (DE-588)4121288-5 gnd Folate (DE-588)4154952-1 gnd Chemotherapie (DE-588)4127083-6 gnd |
| subject_GND | (DE-588)4148337-6 (DE-588)4121288-5 (DE-588)4154952-1 (DE-588)4127083-6 |
| title | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole |
| title_auth | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole |
| title_exact_search | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole |
| title_full | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings |
| title_fullStr | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings |
| title_full_unstemmed | Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings |
| title_short | Inhibition of folate metabolism in chemotherapy |
| title_sort | inhibition of folate metabolism in chemotherapy the origins and uses of co trimoxazole |
| title_sub | the origins and uses of co-trimoxazole |
| topic | Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd Folsäure (DE-588)4121288-5 gnd Folate (DE-588)4154952-1 gnd Chemotherapie (DE-588)4127083-6 gnd |
| topic_facet | Folic Acid Antimetabolites Sulfamethoxazole Pharmacodynamics Trimethoprim Antibiotica Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica Foliumzuur Inhibitie Stofwisseling Sulfonamiden Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol Folsäure Folate Chemotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT hitchingsgeorgeh inhibitionoffolatemetabolisminchemotherapytheoriginsandusesofcotrimoxazole AT acarjacquesf inhibitionoffolatemetabolisminchemotherapytheoriginsandusesofcotrimoxazole |